Please assess the completion status of the following clinical trial:

Trial Title: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have diagnosis of T2D according to the World Health Organization Criteria~* Have an HbA1c of 7.0% - 10.5% inclusive, at screening~* Are on a stable treatment of at least 1 antihyperglycemic medication, for at least 3 months prior to screening, and willing to continue the stable treatment for the duration of the study~* These antihyperglycemic medications are accepted in the study~  * DPP-4 inhibitors~ * SGLT2 inhibitors~ * biguanides, such as metformin~ * alpha-glucosidase inhibitors~ * GLP-1 receptor agonists, oral or injectable~ * Sulfonylureas, or~ * Thiazolidinediones.~* Are insulin naïve.~Exceptions:~* short-term insulin treatment for a maximum of 14 days, prior to screening, and prior insulin treatment for gestational diabetes~  * Have a body mass index of ≤45 kg/m².~Exclusion Criteria:~* Have a diagnosis of T1D, latent autoimmune diabetes, or specific type of diabetes other than T2D, for example, monogenic diabetes, diseases of the exocrine pancreas, or drug induced or chemical-induced diabetes.~* Have a history of \>1 episode of ketoacidosis or hyperosmolar state or coma requiring hospitalization within 6 months prior to screening.~* Have had severe hypoglycemia episodes within 6 months prior to screening.~* Have a history of renal transplantation, are currently receiving renal dialysis, or have an estimated glomerular filtration rate.~* Have known hemoglobinopathy, hemolytic anemia or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with the measurement of HbA1c.~* Have had New York Heart Association Class IV heart failure or any of these cardiovascular conditions within 3 months prior to screening~  * acute myocardial infarction~ * cerebrovascular accident (stroke), or~ * coronary bypass surgery.~* Have had gastric bypass (bariatric) surgery, restrictive bariatric surgery, for example Lap-Band, or sleeve gastrectomy within 1 year prior to screening~* Have had significant weight gain or loss within 3 months prior to screening, for example, ≥5%.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin Efsitora Alfa (Type: EXPERIMENTAL): Participants will receive insulin efsitora alfa subcutaneously (SC) once weekly.
- Insulin Degludec (Type: ACTIVE_COMPARATOR): Participants will receive insulin degludec SC once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).